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1. Introduction 
Rifampicin prevents the formation of foci of Rous 
cells (phenotypically transformed chick embryo 
fibroblasts) at concentrations which do not affect 
virus replication [l] . However, focus inhibition may 
not be due to a specific action of the drug on cell 
transformation but to the toxicity of the doses used 
for tissue culture cells [2] , and notably for trans- 
formed cells [3] . 
On the other hand, rifampicin is not an inhibitor 
in vitro of mammalian DNA-dependent RNA poly- 
merase [4] , nor of RNA-dependent DNA polymerase 
of RNA tumor viruses [5] and, therefore, it does 
not appear to be a good candidate for interfering 
specifically with the replication of RNA tumor 
viruses if this replication involves a DNA interme- 
diate, as suggested by in vitro studies [6-l 0] and 
by the recent finding of infectious DNA in RSV- 
transformed cells [ 11, 121. 
New rifamycin derivatives have now been synthe- 
sized which are powerful inhibitors of the RNA-de- 
pendent DNA polymerase of MSV [ 131. Especially 
active are the 3-oxime derivatives such as AF/O5 
and AF/013 which have also been shown to inhibit 
DNA-dependent RNA polymerase by preventing 
initiation, but not elongation of the initiated RNA 
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chains [ 14, 151. We have examined the effect of the 
rifamycins AF/05 and AF/013 on the replication 
of a clonal isolate of Schmidt-Ruppin strain Rous 
sarcoma virus (SR4) in chick embryo fibroblasts and 
have found that they do not inhibit transformation 
of infected cells, as measured by focus formation, 
at nontoxic doses, whereas virus production is re- 
duced markedly in transformed, but not in newly in- 
fected untransformed cells. 
2. Experimental 
Medium: Standard growth medium was double 
strength Eagle’s MEM supplemented with nonessen- 
tial amino acids (also double strength), 5% calf serum, 
1% tryptose phosphate broth (Difco), and the usual 
antibiotics (penicillin and streptomycin). 
3. Results and discussion 
As seen in fig. 1, the growth of subcultured fibro- 
blasts obtained from whole chick embryos [ 161 is 
not affected by AF/05 and AF/013 concentrations 
up to 20 pg/ml and their cloning efficiency is equally 
resistant to AF/Ol3. Focus formation following in- 
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Fig. I. A) Two days growth of sub~ult~Ired chick embryo 
fibroblasts (seeded at 2 X 10h cells/plate (i:alcon, 6 cm)) in 
medium containing rifamycin Al‘/05 (0) or AI;/01 3 (0) at 
various concentrations. Cells were counted after trypsiniza- 
tion. Untreated control cellsgrew up to 7.5 X 106/plate 
(mean of two plates). B) Formation of foci of Rous cells in 
monolayers of subcultured fibroblasts (2 X 1 06/plate) in- 
fected 1 day after seeding with about 100 I:l:U of SR4 and 
incubated in the presence of various concentrations of‘ A!;/ 
05 and AI:/01 3. added 2 hr before infection. The infected 
cultures were incubated 5 days at 37” under medium gelled 
with agar (Difco. 0.7%) and containing the antibiotics, then 
3 more days under normal gelled medium. 
fection with SR4 is not affected either by antibiotic 
concentrations which do not affect cell growth when 
the monolayer cultures are exposed to the drugs 
2 hr before infection and grown subsequently for 
5 days in their presence and 3 more days in their 
absence; however, the mean diameter of foci is re- 
duced 2-fold compared to controls, and up to &fold 
when rifamycin AFjOl3 is present m the medium for 
8 days from the time of infection. 
On the other hand, the production of free virus 
2 days after infection of the cells is not in~libited 
by the two rifamycin derivatives added at the time 
of infection, but the 2 days virus production of es- 
tablislled transformed Rous cells is strongly reduced 
by the two compounds at concentrations which do 
not significantly affect multiplication of the trans- 
formed cells (fig. 2). The production of virus becomes 
sensitive to AFjOl3 between the second and third 
day after infection which corresponds to the appear- 
ance of Rous cells (fig. 3). 
i~ibition of virus production also depends on 
the proportion of Rous cells: when this proportion 
is over 9%, virus production is reduced about lo-fold, 
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Fig. 2. Growth and two days virus production of fibroblasts 
infected de nova with SR4 (0.1 FFU/cell) and of Rous cells 
in the presence of A17105 (open symbols) and AF’/O13 (filled 
symbols) o, l : normal cells; A, A: Rous ceils ( > 90% of the 
total culture). Cell growth was measured as in fig. 1 and 
virus production by the focus assay of free virus. 
whereas when it is only about 50% i~ibition is only 
2-fold. On the other hand, ROW cells do not detach 
preferentially after treatment with the antibiotic. 
The inhibition of virus production is not due 
either to a decreased infectivity of the virus produced 
in the presence of the drugs since, as shown in fig. 4, 
the decrease of FFUs of virus is paralleled by a de- 
crease of the number of virus particles released in the 
medium, as detected by labelling with [“HI uridine 
and centrifuging in a sucrose gradient [ 171 It can 
also be seen that overall RNA synthesis in Rous cells 
is much less affected by AF/013 than virus production 
and that DNA synthesis is not significantly affected. 
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Fig. 3. Inhibition of virus production by different concen- 
trations of AF/013 as a function of time after infection. 
Replicate fibroblast monolayers were infected with SR4 
(0.1 FFU/cell) and treated with AF/O13 for the following 
times: 0 to 1 day: (0); 1 to 2 days: (0); 2 to 3 days: (A); 
6 to 7 days: (A). Results are expressed as percent of the 
production of the respective untreated controls after the 
period of contact. 
In order to demonstrate that the sensitivity of 
virus production only depends on the transformed 
phenotype of infected cells, advantage was taken of 
the characteristics of a temperature-sensitive mutant 
of SR4, FU-19, which fails to convert infected cells 
to Rous cells at 41” although it retains its capacity 
to replicate at this temperature. Furthermore, Rous 
cells appearing at 37” in infected cultures recover a 
phenotype within a few hours when cultures are 
shifted to 4 l”, and no macromolecular synthesis is 
required for this “detransfomration” [ 181 After in- 
fection 
cultures were incubated at 37” which led to trans- 
formation of about half the cells within 4-5 days. 
The plates were then and incubated either at 
37” or at 41” for one more day; Rous cells thus al- 
most completely disappeared by “detransformation” 
infected plates at 41’. The cul- 
tures were then incubated another 
AF/O13, and free 
virus titrated. As seen in fig. 5, no inhibition 
occurred in detrans- 
whereas virus 
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Fig. 4. Incorporation of [3H] uridine (25 Ci/mmole) and 
[3H]thymidine (25 Ci/mmole) by Rous cells (about 70% of 
the total culture) and free virus released in the medium, in 
the presence of various concentrations of AF/Ol3. Medium 
containing 30 &X/ml of [ 3H]uridine or 12 pCi/ml of [ 3H]- 
thymidine was added to transformed cultures in the pres- 
ence of the antibiotic; after 24 hr incubation at 37”. the 
medium was harvested and centrifuged 15 min at 8000 rpm; 
1.5 ml of-the clarified supernatant was layered on top of a 
sucrose gradient and centrifuged for determination of the 
[3H] uridine incorporated into virus particles [ 171 (a). In 
parallel, an aliquot was titrated for FFUs (0). The radioac- 
tivity incorporated in the cell RNA and DNA (0: [ 3H]uri- 
dine; o: [3H]thymidine) was determined by a new proce- 
dure (De Carli et al., in preparation). 
tion was inhibited in transformed cultures main- 
tained at 37”. 
These findings demonstrate that the two Rifamy- 
tins inhibit the replication of RSV at doses which 
do not affect cell growth, but only in transformed 
cells. Therefore, the transformed phenotype either 
favours penetration of the antibiotics or their access 
to the intracellular site where they interfere with 
viral replication, and some step of this replication 
is blocked selectively. 
Since in transformed cells RNA-dependent DNA 
polymerase is, in principle, no more required for 
virus replication [ 191, and since AF/013 is active on 
DNA-dependent RNA polymerase [ 14, 151 and RSV 
replication depends on DNA-dependent RNA syn- 
thesis [20, 2 l] , the inhibition of RSV production by 
the rifamycins could be at the stage of transcription 
Volume 24, number 3 FEBS LETTERS August 1972 
f r---- 1 
,ug/ml AF/Of3 
Fig. 5. Inhibition of virus production in cells transformed by 
SR4 (wild type virus; open symbols) and by FU-19 (ts mu- 
tant of SR4) (filled symbols) after 24 hr incubation with 
AF/Ol3. o, l : cells incubated at 37”; o, =: cells incubated 
at 41”. 
of the viral DNA template required for the synthesis 
of copies of viral RNA. Furthermore, since overall 
cellular RNA synthesis is much less affected by the 
antibiotics than virus production, it may be that 
tran~ription of the viral DNA template requires a 
special DNA-dependent RNA polymerase which 
could be virus-coded. 
The results presented also show that the rifamy- 
tin derivatives studied do not inhibit the process of 
cell transformation. Hence, the reduction of the size 
of foci of Rous cells observed in the experiments is 
presumably due to reduction of recruiting of new 
cells by infection following the reduction of virus 
production in the transformed cells. 
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